Associations of non-high-density lipoprotein cholesterol, triglycerides and the total cholesterol/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population

Jia Wen¹,² · Yun Huang³ · Yao Lu² · Hong Yuan¹,²

Received: 6 September 2018 / Revised: 10 January 2019 / Accepted: 21 February 2019 / Published online: 27 March 2019 © The Author(s) 2019. This article is published with open access

Abstract
Several lipid parameters are closely associated with residual cardiovascular risk. We aimed to confirm that in a range of low-density lipoprotein cholesterol (LDL-c) levels (from <70 mg/dl to ≥160 mg/dl), other lipid parameters, such as triglyceride (TG) level, non-high-density lipoprotein cholesterol (non-HDL-c) level, and the total cholesterol (TC)/HDL-c ratio, are still related to arterial stiffness, which is a recognized marker of atherosclerosis. In this cross-sectional study, we measured brachial-ankle pulse wave velocity (baPWV), as well as clinical and biochemical indices in 16,733 Chinese adult volunteers who underwent health check-ups from January 2014 to January 2015. Arterial stiffness was defined as the upper quartile of baPWV. We applied multivariable logistic regression models to examine the associations between lipid parameters and arterial stiffness. Both men and women with high baPWV were more likely to have an atherogenic lipid phenotype. Among participants with LDL-c <70 mg/dl, participants with non-HDL-c ≥100 mg/dl had a multivariable adjusted OR for arterial stiffness of 1.66 (1.11–2.50) compared to those with non-HDL-c <100 mg/dl; participants with TG ≥150 mg/dl had an OR of 2.44 (1.61–3.71) compared to those with TG <150 mg/dl; and participants with a TC/HDL-c ratio ≥4 had an OR of 1.74 (1.15–2.65) compared to those with a TC/HDL-c ratio <4. Similar results were observed at other LDL-c levels. We found that non-HDL-c, TG, and the TC/HDL-c ratio were consistently associated with arterial stiffness in a range of LDL-c levels, even when LDL-c was below 70 mg/dl. These lipid measures are related to residual cardiovascular risk, possibly due to their detrimental effects on vascular structure.

Keywords Low-density lipoprotein cholesterol · Non-high-density lipoprotein cholesterol · Triglycerides · Total cholesterol/HDL-c ratio · Brachial-ankle pulse wave velocity · Arterial stiffness · Cardiovascular disease

Introduction
Cardiovascular disease (CVD) is a public health issue worldwide [1]. Low-density lipoprotein cholesterol (LDL-c) plays a central role in the development of CVD events [2, 3]. Consequently, contemporary guidelines focus on reducing LDL-c as the primary therapeutic target [4, 5]. According to the National Cholesterol Education Program Adult Treatment Panel III Guidelines update in 2004 [4], the LDL-c goal is <100 mg/dl for high-risk patients, and a lower LDL-c goal (<70 mg/dl) is recommended for those with extremely high risk. Despite being on statin treatment, many patients with low LDL-c still experience adverse clinical outcomes; this situation is referred to as residual risk [6–8]. The predictors of residual risk include lipid-related and nonlipid factors [9, 10]. Among lipid-related factors, high-density lipoprotein cholesterol (HDL-c), triglycerides (TG), non-HDL-c, and the TC/HDL-c ratio are commonly implicated [6–8].

Arterial stiffness is a well-established marker for atherosclerosis and occurs prior to adverse cardiovascular events...
Clinical and biochemical data were obtained as previously described [22]. Briefly, baseline information on demographics, health-related habits, medical history, and current medication use was collected using a standardized questionnaire. Smoking or drinking was defined as ‘current’ (smoking or drinking in the past 6 months or quit smoking or drinking within the past 6 months), ‘former’ (had stopped smoking or drinking for more than 6 months), or ‘never’ [22]. Exercise habits were defined according to frequency per week (≤2 times/week or ≥3 times/week, with the latter indicating that the individual was physically active) [22]. Anthropometrics were measured by trained staff. Body height and weight were recorded to the nearest 0.1 cm and 0.1 kg, respectively, while participants were wearing light indoor clothing without shoes. BMI was calculated in kg/m². Waist circumference (WC) was measured at the middle point between the costal margin and the iliac crest. Blood pressure (BP) was measured with the participant in the seated position based on the Joint National Committee (JNC) 7 report: [23] three readings were taken at 5-min intervals, and a mean was calculated, but if the difference between any two readings was greater than 10 mmHg, the 2 closest measurements were used. Blood samples were collected in the morning after an overnight fast of at least 8 h. Serum FPG, TG, TC, LDL-c, HDL-c, and Scr levels were determined using an autoanalyzer (Hitachi 7600–110; Hitachi, Tokyo, Japan). Non-HDL-c was calculated as TC minus HDL-c.

We measured baPWV with a noninvasive atherosclerosis measurement system (VP-2000; Colin Co Ltd, Komaki, Japan). All the subjects were asked to refrain from smoking or alcohol before the tests. Measurements were taken in a room at constant temperature after the individuals had rested in the supine position for 10 min. Four pneumatic cuffs were attached to bilateral arms and ankles to measure pulse waves [24]. The baPWV was automatically calculated as follows: $\text{baPWV} = \frac{(L_b - L_s)}{L_a} / T_{ba}$ ($L_a$ is the distance from the heart to the ankle, $L_b$ is the distance from the heart to the brachium, and $T_{ba}$ is the time difference between the initial increase in the brachial waveform and that in the ankle waveform) [24]. ABI (the ratio of SBP in the leg to that in the arm on the same side) and heart rate were also automatically recorded.

**Definitions of hypertension, diabetes, and dyslipidemia**

Hypertension was defined as systolic BP (SBP) ≥140 mmHg, diastolic BP (DBP) ≥90 mmHg or the use of anti-hypertensive medication. Diabetes was defined as FPG ≥126 mg/dl or the use of insulin or oral hypoglycemic
medication. Low HDL-c was defined as <40 mg/dl in men and <50 mg/dl in women. Dyslipidemia was defined as LDL-c ≥ 140 mg/dl, TG ≥ 150 mg/dl, low HDL-c or current use of antidyislipidemic medication. High baPWV was defined as the upper quartile of baPWV [25].

**Statistical analysis**

Continuous data are expressed as the mean ± standard deviation or median with interquartile range, and categorical data are expressed as proportions. Continuous data for participants with high baPWV and those with low baPWV were compared with the t-test or the Mann–Whitney U test, and categorical data were analyzed by the chi-square test. The multivariable logistic regression model was utilized to evaluate the association of high baPWV with predefined cut-off values of LDL-c (<70 mg/dl, 70–99.9 mg/dl, 100–129.9 mg/dl, ≥130 mg/dl), non-HDL-c (<100 mg/dl, 100–129.9 mg/dl, 130–159.9 mg/dl, ≥160 mg/dl), TGs (<150 mg/dl, 150–199.9 mg/dl, 200–249.9 mg/dl, ≥250 mg/dl), and the TC/HDL-c ratio (<4.00, 4.00 to 4.99, 5.00 to 5.99, ≥6.00) based on current guidelines and studies [4, 8]. Because of the skewed distribution, TG levels were log-transformed. Each lipid parameter was then examined as a continuous variable (per 1-SD increment) in the above-mentioned model. We also calculated the odds ratios (ORs) for high baPWV with elevated non-HDL-c (30 mg/dl higher than the maximal LDL-c level), TGs (≥150 mg/dl), or TC/HDL-c ratio (≥4.00) across different levels of LDL-c (<70 mg/dl, 70–99.9 mg/dl, 100–129.9 mg/dl, and ≥130 mg/dl). All the analyses were adjusted for variables associated with PWV, including age, sex (total), smoking and drinking status, physical activity, BMI, HR, FPG, SBP, pulse pressure, Cr, low HDL-c, and medications for diabetes, hypertension, or dyslipidemia [21, 26]. The variance inflation factor (VIF) was used to detect collinearity, with a VIF ≥ 10 indicating a collinearity problem. Statistical analyses were performed with SPSS 22.0 (SPSS Inc., Chicago, IL). We corrected for multiple comparisons to ensure that none of the independent tests using the Li and Ji method [27]. Thus, a P value less than 0.025 (0.05/2) was considered to indicate statistical significance.

**Results**

The mean age of the entire cohort was 48.4 years, and 62% of the participants were male. Among the male study participants, 26.5% were in the high baPWV group, and among the female study participants, 22.7% were in the high baPWV group. The general characteristics of the high baPWV and low baPWV groups stratified by gender are described in Table 1. Among both genders, the high baPWV group was older and more frequently had a history of hypertension, diabetes, and dyslipidemia than the low baPWV group. Antihypertensive, hypoglycemic, and lipid-lowering agents were more frequently used in the high baPWV group. Higher BMI, WC, HR, and BP and FPG, TC and non-HDL-c levels were also detected in the high baPWV group. However, LDL-c and the TC/HDL-c ratio were significantly different between women with and without high baPWV but not between men with and without high baPWV.

Table 2 shows the adjusted ORs for the prevalence of high baPWV according to LDL-c, non-HDL-c, and TG levels and the TC/HDL-c ratio. No collinearity was observed between variables. Compared to participants with non-HDL-c <100 mg/dl, the multivariable adjusted ORs ranged from 1.25 (95% CI, 1.04–1.51) among participants with non-HDL-c of 100–129.9 mg/dl to 1.46 (95% CI, 1.22–1.75) among participants with non-HDL-c ≥160 mg/dl (P < 0.001 for trend). Similarly, elevated TGs and the TC/HDL-c ratio were associated with a greater prevalence of high baPWV. No significant association was detected between high baPWV and LDL-c, and there were no significant interactions between sex and lipid categories.

Table 3 presents the adjusted ORs for the prevalence of high baPWV associated with a 1-SD increase in lipid profile. After adjusting for all the confounding factors, the ORs for high baPWV per 1-SD increase in lipid profile were 1.12 (95% CI, 1.06–1.17) for non-HDL-c, 1.22 (95% CI, 1.16–1.29) for TG, and 1.15 (95% CI, 1.09–1.22) for the TC/HDL-c ratio. Again, LDL-c was not associated with high baPWV. We found a significant interaction between sex and LDL-c in the prediction of high baPWV risk (P = 0.025), but there were no other sex-lipid interactions.

Table 4 shows the association between non-HDL-c, TGs, or the TC/HDL-c ratio and high baPWV across a range of LDL-c values from <70 mg/dl to ≥130 mg/dl. Even among individuals with LDL-c <70 mg/dl, elevated non-HDL-c, TGs and TC/HDL-c ratio were associated with high baPWV. Among participants with an LDL-c of 100–129.9 mg/dl, non-HDL-c and TGs as categorical variables were not independent risk factors for high baPWV, but non-HDL-c and TGs as continuous variables revealed a significant association.

**Discussion**

In this large population-based study, we observed that non-HDL-c, TG, and the TC/HDL-c ratio, but not LDL-c, were consistently and positively associated with arterial stiffness, as defined by high baPWV, independent of CVD risk factors. In addition, positive associations were consistently observed for non-HDL-c, TGs and the TC/HDL-c ratio.
within every LDL-c level investigated, including LDL-c <70 mg/dl. TGs may be more predictive of arterial stiffness than non-HDL-c and the TC/HDL-c ratio.

Our observation shows that non-HDL-c, TG, and the TC/HDL-c ratio were associated with arterial stiffness is consistent with most previous studies, although different indices were adopted [16–20]. Non-HDL-c was calculated as TC minus HDL-c and thus included all atherogenic lipoproteins (VLDL, intermediate-density lipoprotein cholesterol (IDL-c), LDL-c, and lipoprotein(a)) [5]. Non-HDL-c was identified as a good predictor of subclinical atherosclerosis in a Dutch cohort including 1517 individuals based on the detection of a lower ABI, a higher augmentation index, thicker plaques, increased PWV, and increased intima-media thickness [16]. Similarity, Ma et al. [17]. determined that non-HDL-c was independently correlated with carotid intima-media thicknesses in normotensive and normoglycemic females. Elevated nonfasting serum TGs indicates elevated lipoprotein remnants (VLDL, IDL-c, and chylomicrons remnants), which can penetrate the vascular endothelium and lead to atherosclerosis [28]. Two recent studies involving Chinese adults who underwent health examinations demonstrated that elevated TG levels were associated with baPWV [18, 20]. Another study of 2351 Caucasian adults revealed a positive association between TG levels and baPWV in males [19]. The TC/HDL-c ratio

### Table 1 Characteristics of study subjects stratified by brachial-ankle pulse wave velocity and gender

|                      | Men Low baPWV | High baPWV | Women Low baPWV | High baPWV |
|----------------------|----------------|------------|-----------------|------------|
| **Number**           | 7572           | 2724       | 4978            | 1459       |
| **Age (years)**      | 45.3 ± 9.7     | 57.3 ± 11.9 | 45.2 ± 9.9      | 59.3 ± 9.1 |
| **Current smoking (%)** | 57.4        | 48.9<sup>c</sup> | 5.2            | 3.5<sup>a</sup> |
| **Current drinking, (%)** | 70.9        | 58.8<sup>c</sup> | 27.4           | 15.6<sup>c</sup> |
| **Physical activity (%)** | 37.6        | 52.6<sup>c</sup> | 40.2           | 51.2<sup>c</sup> |
| **BMI (kg/m²)**      | 25.2 ± 3.1     | 25.4 ± 3.1<sup>a</sup> | 23.0 ± 3.1    | 24.6 ± 3.0<sup>c</sup> |
| **WC (cm)**          | 87.1 ± 8.6     | 88.2 ± 8.5<sup>c</sup> | 76.9 ± 8.3    | 82.7 ± 8.4<sup>a</sup> |
| **HR (b/min)**       | 70.4 ± 10.5    | 75.6 ± 12.3<sup>c</sup> | 71.1 ± 10.1    | 74.6 ± 11.9<sup>c</sup> |
| **SBP (mmHg)**       | 122.2 ± 12.3   | 138.7 ± 6.1<sup>c</sup> | 115.8 ± 13.6  | 139.8 ± 17.3<sup>c</sup> |
| **DBP (mmHg)**       | 78.0 ± 10.0    | 86.2 ± 12.1<sup>c</sup> | 71.8 ± 9.6    | 81.8 ± 11.6<sup>c</sup> |
| **Pulse pressure (mmHg)** | 44.2 ± 8.3  | 52.6 ± 12.6<sup>c</sup> | 44.0 ± 9.0    | 58.1 ± 13.4<sup>c</sup> |
| **Hypertension (%)** | 18.4           | 61.4<sup>c</sup> | 8.9            | 60.1<sup>c</sup> |
| **Antihypertensive drugs (%)** | 6.1         | 25.4<sup>c</sup> | 3.8            | 28.8<sup>c</sup> |
| **FPG (mg/dl)**      | 96.6 ± 20.8    | 108.8 ± 37.3<sup>c</sup> | 92.1 ± 13.1   | 104.9 ± 31.2<sup>c</sup> |
| **Diabetes (%)**     | 4.7            | 13.4<sup>c</sup> | 1.5            | 10.3<sup>c</sup> |
| **Antidiabetic drugs (%)** | 2.1         | 7.6<sup>c</sup> | 0.8            | 6.0<sup>c</sup> |
| **TG, mg/dl**        | 140.9(97.5–208.3) | 145.8(100.2–221.4)<sup>c</sup> | 90.4(67.4–127.6) | 127.6(93.9–176.4)<sup>c</sup> |
| **TC (mg/dl)**       | 202.5 ± 38.1   | 206.3 ± 44.5<sup>c</sup> | 198.0 ± 37.4   | 215.1 ± 39.6<sup>c</sup> |
| **LDL-c (mg/dl)**    | 111.9 ± 32.7   | 110.5 ± 34.6<sup>c</sup> | 107.4 ± 31.9   | 120.0 ± 34.1<sup>c</sup> |
| **HDL-c (mg/dl)**    | 55.4 ± 13.4    | 56.9 ± 14.9<sup>c</sup> | 69.1 ± 15.4    | 65.5 ± 15.2<sup>c</sup> |
| **Non-HDL-c (mg/dl)** | 147.1 ± 38.2 | 149.5 ± 44.3<sup>a</sup> | 128.9 ± 36.9   | 149.6 ± 38.3<sup>c</sup> |
| **TC/HDL-c ratio**   | 3.84 ± 1.02    | 3.83 ± 1.09<sup>c</sup> | 3.13 ± 0.79    | 3.41 ± 0.83<sup>c</sup> |
| **Dyslipidaemia (%)** | 56.7         | 59.9<sup>b</sup> | 28.5           | 53.1<sup>c</sup> |
| **Lipid-lowering drugs (%)** | 1.0        | 2.7<sup>c</sup> | 0.9            | 2.3<sup>c</sup> |
| **Serum creatinine (mg/dl)** | 0.87 ± 0.14 | 0.90 ± 0.26<sup>c</sup> | 0.61 ± 0.10    | 0.66 ± 0.21<sup>c</sup> |
| **eGFR, mL/min/1.73 m²** | 108.9 ± 21.4 | 103.4 ± 24.9<sup>c</sup> | 132.9 ± 28.3   | 118.6 ± 30.1<sup>c</sup> |
| **baPWV (cm/s)**     | 1299.6 ± 129.9 | 1777.7 ± 263.9<sup>c</sup> | 1239.4 ± 150.7 | 1794.7 ± 266.3<sup>c</sup> |

Values are presented as the mean ± standard deviation (median with interquartile range) or proportion

BMI body mass index, WC waist circumference, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, TC triglyceride, TC total cholesterol, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol, eGFR estimated glomerular filtration rate, baPWV brachial-ankle pulse wave velocity

<sup>a</sup>P < 0.05, <sup>b</sup>P < 0.01, <sup>c</sup>P < 0.001
Table 2 ORs for high baPWV stratified by LDL-c, non-HDL-c, and TG levels and the TC/HDL-c ratio

|                      | LDL-c (mg/dl) |          |          |          |          |          |          |
|----------------------|--------------|----------|----------|----------|----------|----------|----------|
|                      | <70          | 70–99.9  | 100–129.9| ≥130     |          |          |          |
| Total (OR)           | 1.00         | 0.92(0.76–1.11)| 0.91(0.76–1.09)| 0.98(0.81–1.18)| 0.701    |
| Men (OR)             | 1.00         | 0.86(0.69–1.06)| 0.81(0.66–1.00)| 0.87(0.70–1.08)| 0.427    |
| Women (OR)           | 1.00         | 1.15(0.78–1.70)| 1.17(0.80–1.70)| 1.18(0.80–1.73)| 0.556    |
| Non-HDL-c (mg/dl)    | <100         | 100–129.9| 130–159.9| ≥160     |          |          |          |
| Total (OR)           | 1.00         | 1.25(1.04–1.51)| 1.18(0.99–1.42)| 1.46(1.22–1.75)| <0.001   |
| Men (OR)             | 1.00         | 1.24(0.98–1.58)| 1.12(0.89–1.41)| 1.36(1.08–1.71)| 0.015    |
| Women (OR)           | 1.00         | 1.17(0.85–1.62)| 1.13(0.83–1.54)| 1.36(0.99–1.86)| 0.055    |
| TGs (mg/dl)          | <150         | 150–199.9| 200–249.9| ≥250     |          |          |          |
| Total (OR)           | 1.00         | 1.09(0.96–1.25)| 1.33(1.12–1.58)| 1.48(1.28–1.72)| <0.001   |
| Men (OR)             | 1.00         | 1.06(0.90–1.25)| 1.30(1.07–1.59)| 1.51(1.27–1.78)| <0.001   |
| Women (OR)           | 1.00         | 1.06(0.83–1.34)| 1.27(0.90–1.80)| 1.19(0.82–1.69)| 0.209    |
| TC/HDL-c             | <4.00        | 4.00–4.99 | 5.00–5.99| ≥6.00    |          |          |          |
| Total (OR)           | 1.00         | 1.19(1.06–1.34)| 1.27(1.05–1.55)| 1.56(1.09–2.21)| <0.001   |
| Men (OR)             | 1.00         | 1.11(0.97–1.28)| 1.22(0.99–1.50)| 1.50(1.04–2.18)| 0.009    |
| Women (OR)           | 1.00         | 1.37(1.07–1.76)| 1.35(0.79–2.30)| 1.62(0.50–5.26)| 0.013    |

The values are presented as the odds ratio (OR) (95% confidence interval); ORs were obtained after adjusting for age, sex (total), smoking and drinking status, physical activity, BMI, HR, FPG, SBP, pulse pressure, Cr, low HDL-c, and medications for diabetes, hypertension, and dyslipidaemia.

OR odds ratio; other abbreviations are as listed in Table 1.

Table 3 ORs for high baPWV per 1-SD increase in LDL-c, non-HDL-c, and TG levels and the TC/HDL-c ratio

|                      | SD           | OR (95% CI) | P value |
|----------------------|--------------|-------------|---------|
| LDL-c                |              |             |         |
| Total                | 33.1         | 1.01(0.96–1.06)| 0.653   |
| Men                  | 33.3         | 0.97(0.91–1.03)| 0.275   |
| Women                | 32.8         | 1.05(0.96–1.15)| 0.278   |
| Non-HDL-c            |              |             |         |
| Total                | 39.9         | 1.12 (1.06–1.17)| <0.001  |
| Men                  | 39.1         | 1.10 (1.04–1.17)| 0.002   |
| Women                | 38.2         | 1.08 (0.99–1.19)| 0.087   |
| TGs<sup>a</sup>      |              |             |         |
| Total                | 149.1        | 1.22 (1.16–1.29)| <0.001  |
| Men                  | 172.4        | 1.22 (1.14–1.30)| <0.001  |
| Women                | 85.8         | 1.16 (1.03–1.30)| 0.012   |
| TC/HDL-c             |              |             |         |
| Total                | 1.02         | 1.15 (1.09–1.22)| <0.001  |
| Men                  | 1.03         | 1.12 (1.05–1.20)| 0.001   |
| Women                | 0.82         | 1.17 (1.04–1.32)| 0.009   |

The values are presented as the odds ratio (OR) (95% confidence interval); ORs were obtained after adjusting for age, sex (total), smoking and drinking status, physical activity, BMI, HR, FPG, SBP, pulse pressure, Cr, low HDL-c, and medications for diabetes, hypertension, and dyslipidaemia.

SD standard deviation; other abbreviations are as listed in Table 1.

<sup>a</sup>The variable is presented as the original value after analysis using the log-transformed value.
has been suggested as a useful cumulative index of the atherogenic lipid phenotype and was found to be associated with insulin resistance in the Quebec Cardiovascular Study [29]. Moreover, data from two prospective cohorts [30, 31] involving 14,916 initially healthy US males and 27,935 females confirmed that the TC/HDL ratio was significantly associated with peripheral arterial disease incidence. We are the first to report the association between the TC/HDL ratio and PWV. Our study did not demonstrate a relationship between LDL-c and high baPWV, which is in line with previous findings [18, 32]. We suspect that the influence of LDL-c was hidden by other, stronger risk factors, such as age, hypertension, and diabetes. Interestingly, Brinkley et al. [33] showed that elderly participants with elevated oxidized LDL-c were 30 to 55% more likely to have high aortic PWV.

LDL-c is the primary target of therapy according to current guidelines; [4, 5] however, whether any of the aforementioned relationships remain when the LDL-c is lower continues to be an unsolved but important issue. Meanwhile, other on-treatment lipid levels are related to a residual risk of CVD among a subset of subjects with low LDL-c [6–8]. In a post hoc analysis of the TNT (Treating to New Targets) and IDEAL (Incremental Decrease in End Points through Aggressive Lipid Lowering) trials [6], the hazard ratios for future cardiovascular events (per 1-SD increase) were 1.15 (1.05–1.25) for non-HDL-c, 1.15 (1.05–1.25) for apolipoprotein B, 1.22 (1.14–1.30) for the TC/HDL-c ratio, and 1.31 (1.21–1.41) for the apolipoprotein B/A-1 ratio among patients with LDL-c under 100 mg/dl; however, TGs were not evaluated. In the EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk study [7], non-HDL-C, TGs, and the TG/HDL-c ratio were all strongly associated with future coronary heart disease (CHD), with hazard ratios of 1.84 (1.12–3.04), 1.63 (1.02–2.59), and 2.19 (1.22–3.93), respectively, among individuals with LDL-c below 100 mg/dl. In the subanalysis of participants with LDL-c less than 100 mg/dl in the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) study [8], non-HDL-c was valuable in predicting CVD incidence, and the TC/HDL-c ratio was borderline significant, whereas TGs were not associated with CVD. To the best of our knowledge, the present study is the first to report significant positive associations of non-HDL-c, TGs, and the TC/HDL-c ratio with arterial stiffness irrespective of LDL-c level, especially among participants with naturally very low LDL-c (<70 mg/dl). Our research adds novel evidence that these lipid parameters are closely associated with high residual cardiovascular risk, possibly because of additional deleterious effects on arterial stiffness.

Previous evidence generally supports a causal relationship between lipids and vascular stiffness. Several clinical trials have demonstrated that lipid-lowering therapy improves baPWV [34–37]. A recent meta-analysis by Upala et al. [38] involving 303 participants also reported that statin therapy was associated with lower aortic PWV. However, it should be noted that limited numbers of participants have been included in these studies. In addition, several lifestyle changes, including weight loss, physical exercise, salt reduction, and cessation of smoking or drinking, have beneficial effects on vascular stiffness [11].

### Table 4

| LDL-c < 70 | Non-HDL-c < 100 | Non-HDL-c ≥ 100 | TG < 150 | TG ≥ 150 | TC/HDL-c < 4 | TC/HDL-c ≥ 4 |
|------------|----------------|----------------|----------|----------|--------------|--------------|
| LDL-c 70–99.9 | 1.00 | 1.66 (1.11–2.50) | 1.00 | 2.44 (1.61–3.71) | 1.00 | 1.74 (1.15–2.65) |
| LDL-c ≥ 100 | 1.00 | 1.46 (1.15–1.85) | 1.00 | 1.42 (1.12–1.80) | 1.00 | 1.39 (1.07–1.81) |
| LDL-c ≥ 130 | 1.00 | 1.20 (0.96–1.50) | 1.00 | 1.19 (0.95–1.50) | 1.00 | 1.06 (0.87–1.29) |

The values are presented as the odds ratio (OR) (95% confidence interval); ORs were obtained after adjustments for age, sex, smoking and drinking status, physical activity, BMI, HR, FPG, SBP, pulse pressure, Cr, low HDL-c, and medications for diabetes, hypertension, and dyslipidaemia. OR odds ratio; other abbreviations are as listed in Table 1.

*The variable is presented as the original value after analysis using the log-transformed value.*
Our study has certain limitations. First, the cohort was voluntary, and individuals already under treatment for CVD may not have participated. Therefore, the study may be biased by the healthy worker effect [39]. Second, our cohort consisted of mostly urban participants who underwent health examinations. These subjects were relatively younger, with a mean age of 48.4 ± 11.5 years, and thus might have been more likely to be concerned about their health than the general population. For example, the prevalence of diabetes mellitus and obesity in this population was lower than that in the general Chinese population (5.6% vs. 11.6% and 4.7% vs. 12.0%, respectively) [40]. Moreover, HDL-c was higher in these participants than in the general population (60.6 ± 15.7 mg/dl vs. 51.7 ± 11.4 mg/dl) [41], and fewer were on statin treatment (2.6% vs. 6.84%) [42]. Therefore, our findings may be generalized to only relatively healthy and young populations. Finally, due to the cross-sectional study design, it was difficult to infer causality between dyslipidemia and arterial stiffness in our study. Therefore, prospective studies are required to examine the predictive value of the lipid profile for vascular risk in the general population.

In conclusion, this study extends the results of previous studies by demonstrating the associations of non-HDL-c, TG, and the TC/HDL-c ratio with arterial stiffness over a range of LDL-c concentrations, even those that are optimal (<70 mg/dl), among 16,733 relatively healthy individuals. These findings suggest a potential mechanism underlying the residual cardiovascular risk observed in patients with low LDL-c.

Acknowledgements We appreciate all the subjects who participated in this study.

Funding This study was funded by the National Natural Science Foundation of China (No. 81470535) and Major Projects of Science and Technology in Hunan Province (No. 2016SK1001).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease and Stroke Statistics-2016 Update: a report from the American Heart Association. Circulation. 2016;133:e38–360.
2. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. J Am Med Assoc. 2005;294:326–33.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trials’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.
4. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–32.
5. Authors/Task Force Members: Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.
6. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Catter NB, Barter P, et al. TNT Study Group; IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–9.
7. Arsenault BJ, Rana JS, Stroes ES, Despres JP, Shah PK, Kastelein JJ, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009;55:35–41.
8. Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2012;59:1521–8.
9. Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, et al. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012;125:1979–87.
10. Blankstein R, Budoff MJ, Shaw LJ, Goff DC Jr., Polak JF, Lima J, et al. Predictors of coronary heart disease events among asymptomatic persons with low low-density lipoprotein cholesterol MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011;58:364–74.
11. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932–43.
12. Munakata M. Brachial-ankle pulse wave velocity: background, method, and clinical evidence. Pulse. 2016;3:195–204.
13. Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, et al. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens. 2009;27:2022–7.
14. Vlachopoulos C, Aznaouridis K, Terentes-Platziotis D, Ioakeimidis N, Stefanadis C. Prediction of cardiovascular events and all-
cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis. Hypertension. 2012;60:556–62.
15. Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshide S, Kita Y, et al. Collaborative Group for J-BAVEL (Japan brachial-ankle pulse wave velocity individual participant data meta-analysis of prospective studies)*. Brachial-ankle pulse wave velocity and the risk prediction of cardiovascular disease: an individual participant data meta-analysis. Hypertension. 2017;69:1045–52.
16. Holewijn S, den Heijer M, Stalenhoef AF, de Graaf J. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Intern Med. 2010;268:567–77.
17. Ma H, Lin H, Hu Y, Li X, He W, Jin X, et al. Relationship between non-high-density lipoprotein cholesterol and carotid atherosclerosis in normotensive and euglycemic Chinese middle-aged and elderly adults. Lipids Health Dis. 2017;16:55.
18. Wen J, Zhong Y, Kuang C, Liao J, Chen Z, Yang Q. Lipoprotein ratios are better than conventional lipid parameters in predicting arterial stiffness in young men. J Clin Hypertens. 2017;19:771–6.
19. Gomez-Sanchez L, Garcia-Ortiz L, Recio-Rodriguez JI, Fernando R, Marti R, et al. Association of metabolic syndrome and its components with arterial stiffness in Caucasian subjects of the MARK study: a cross-sectional trial. Cardiovasc Diabetol. 2016;15:148.
20. Chen L, Zhu W, Mai L, Fang L, Ying K. The association of metabolic syndrome and its components with brachial-ankle pulse wave velocity in south China. Atherosclerosis. 2015;240:345–50.
21. Tomiyama H, Hashimoto H, Hirayama Y, Yambé M, Yamada J, Koji Y, et al. Synergistic acceleration of arterial stiffening in the presence of raised blood pressure and raised plasma glucose. Hypertension. 2006;47:180–8.
22. Wen J, Chen Y, Huang Y, Lu Y, Liu X, Zhou H, et al. Association of the TG/HDL-C and Non-HDL-C/HDL-C Ratios with Chronic Kidney Disease in an Adult Chinese Population. Kidney Blood Pres Res. 2017;42:1141–54.
23. C Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention detection evaluation and treatment of high blood pressure: the JNC 7 report. J Am Med Assoc. 2003;289:2560–71.
24. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, Hirayama Y, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hyperten Res. 2003;26:615–22.
25. Zhao WW, Yang YH, Lu B, Feng XC, He M, Yang ZH, et al. Serum high-density lipoprotein cholesterol and progression to arterial stiffness in middle-aged and elderly Chinese. Nutr Metab Cardiovasc Dis. 2013;23:973–9.
26. Tomiyama H, Hashimoto H, Tanaka H, Matsumoto C, Odaira M, Yamada J, et al. Continuous smoking and progression of arterial stiffening: a prospective study. J Am Coll Cardiol. 2010;55:1979–87.
27. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005;95:221–7.